Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP OTCMKTS:CVSI OTCMKTS:GSAC NASDAQ:MBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$4.62-3.1%$7.46$3.80▼$44.90$7.32M-1.2786,712 shs90,157 shsCVSICV Sciences$0.04-1.4%$0.04$0.02▼$0.05$6.69M0.61155,270 shs174,266 shsGSACGelStat$0.00$0.00$0.00▼$0.00$1.50M3.033.25 million shsN/AMBIOMustang Bio$1.51-2.3%$1.77$0.89▼$21.95$10.93M2.22152,830 shs74,891 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals0.00%-2.12%-29.14%-39.58%-89.45%CVSICV Sciences0.00%-8.35%+0.56%+31.64%-26.05%GSACGelStat0.00%0.00%+33.33%0.00%0.00%MBIOMustang Bio0.00%-8.48%-1.31%+16.15%-89.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.8895 of 5 stars3.55.00.00.02.51.70.0CVSICV Sciences0.2185 of 5 stars0.03.00.00.02.40.00.0GSACGelStatN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio1.0311 of 5 stars0.05.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$31.00571.00% UpsideCVSICV Sciences 0.00N/AN/AN/AGSACGelStat 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GSAC, MBIO, CVSI, and ACXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$31.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$2.25 per shareN/ACVSICV Sciences$15.70M0.43N/AN/A$0.01 per share3.62GSACGelStatN/AN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/A$0.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$10.69N/AN/AN/AN/A-436.83%-192.25%11/11/2025 (Estimated)CVSICV Sciences-$2.39MN/A0.00∞N/A-10.36%-80.82%-19.38%N/AGSACGelStatN/AN/A0.00∞N/AN/AN/AN/AN/AMBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-29.49%11/6/2025 (Estimated)Latest GSAC, MBIO, CVSI, and ACXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ACXPAcurx Pharmaceuticals-$2.00-$1.89+$0.11-$1.89N/AN/A8/8/2025Q2 2025MBIOMustang BioN/A-$0.19N/A-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/AGSACGelStatN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.382.38CVSICV Sciences0.121.040.30GSACGelStatN/AN/AN/AMBIOMustang BioN/A1.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%CVSICV SciencesN/AGSACGelStatN/AMBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%CVSICV Sciences3.80%GSACGelStat20.50%MBIOMustang Bio0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals31.58 million1.26 millionOptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableGSACGelStat23.74 billion2.97 billionNot OptionableMBIOMustang Bio1007.24 million7.23 millionNot OptionableGSAC, MBIO, CVSI, and ACXP HeadlinesRecent News About These CompaniesMustang Bio Inc.July 25, 2025 | barrons.comTalisker Receives Assay Results from 1105 Level Lateral Development at the Mustang MineJuly 24, 2025 | globenewswire.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - NasdaqJuly 10, 2025 | nasdaq.comMustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer DrugJuly 10, 2025 | msn.comBiotech Stock Mustang Bio, Inc. (Nasdaq: MBIO) Soars on Orphan Drug Designation by U.S. FDAJuly 9, 2025 | investorideas.comIMustang Bio Inc News (MBIO) - Investing.comJuly 9, 2025 | investing.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer TherapyJuly 8, 2025 | zacks.comDow Dips 1%; Mustang Bio Shares Spike HigherJuly 7, 2025 | benzinga.comThis BlackRock stock just spiked over 300%July 7, 2025 | finbold.comFMustang Bio stock soars after FDA grants orphan drug designationJuly 7, 2025 | investing.comMustang Bio rises after FDA orphan drug status for MB-101July 7, 2025 | msn.comMustang Bio Shares Surge After FDA Grants Orphan Drug StatusJuly 7, 2025 | msn.comMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and GlioblastomaJuly 7, 2025 | globenewswire.comMustang Bio, Inc. (MBIO) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comMustang Bio treatment of malignant glioma granted orphan designationJuly 2, 2025 | msn.comMBIO Mustang Bio, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMustang Bio’s first-of-a-kind CAR-T starts trialsMay 1, 2025 | pharmaphorum.comPMustang Bio meets Nasdaq’s equity listing requirementsMarch 7, 2025 | investing.comMustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy AdvancementsMarch 7, 2025 | nasdaq.comMustang Bio regains compliance with Nasdaq requirementMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSAC, MBIO, CVSI, and ACXP Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$4.62 -0.15 (-3.14%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.61 -0.01 (-0.32%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.CV Sciences OTCMKTS:CVSI$0.04 0.00 (-1.36%) As of 08/29/2025 02:32 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.GelStat OTCMKTS:GSAC$0.0004 0.00 (0.00%) As of 08/29/2025GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.Mustang Bio NASDAQ:MBIO$1.51 -0.04 (-2.27%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.53 +0.02 (+1.32%) As of 08/29/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
